Prophylactic or therapeutic drug for neurodegenerative diseases
AssigneeMedilabo Rfp, Inc.
InventorsTakami Tomiyama, Tomohiro Umeda, Toru Kumagai
Life of this patent
Estimating the term…
Abstract
A method for treating tauopathy or synucleinopathy in a patient comprising administering to the patient a pharmacological active component consisting of a combination of: a rifampicin compound selected from the group consisting of rifampicin, a derivative of rifampicin, a salt of rifampicin and a salt of a derivative of rifampicin, and a resveratrol compound selected from the group consisting of resveratrol and a derivative of resveratrol.
Claims2
A method for treating tauopathy or synucleinopathy in a patient comprising administering to the patient a pharmacological active component consisting of a combination of:
- a rifampicin compound selected from the group consisting of rifampicin, a derivative of rifampicin, a salt of rifampicin and a salt of a derivative of rifampicin, and
- a resveratrol compound selected from the group consisting of resveratrol and a derivative of resveratrol;
- wherein the derivative of rifampicin is selected from the group consisting of 3-Formyl-Rifamycin SV, Rifamycin S, Rifamycin B, Rifamycin SV and 25-Desacetyl-RFP, and the derivative of resveratrol is a resveratrol having a derivative group selected from the group consisting of N-phenylacetyl group, 4,4′-dimethoxytrityl (DMT) group, protein group, peptide group, sugar group, lipid group, nucleic acid group, polystyrene group, polyethylene group, polyvinyl polyester group, and ester group.
Dependencies are inferred from the claim text.